SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is trending downwards as community members discuss concerns around potential market manipulation and an AI bubble, especially following earnings. Traders are debating whether to buy the dip or prepare for a larger correction, while monitoring key support levels. Some are pointing to macro factors like interest rate expectations and geopolitical concerns as potential catalysts for further volatility.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Nvidia's stock is trending amid upgrades from analysts, though some community members express concern over valuation relative to competitors and potential interconnect hurdles in the AI sector. Despite strong earnings, the stock experienced a selloff, leading to discussions about a possible short squeeze and whether AI constitutes a bubble.

NIO, Inc. is a holding company which engages in the design, manufacture, and sale of electric vehicles. Its products include the EP9 supercar and ES8 7-seater SUV. It provides users with home charging, power express valet services, and other power solutions including access to public charging, access to power mobile charging trucks, and battery swapping. It also offers other value-added services such as service package, battery payment arrangement, and vehicle financing and license plate registration. The company was founded by Bin Li and Li Hong Qin on November 28, 2014 and is headquartered in Jiading, China.

NIO Inc - ADR

NIO Inc

NIO is trending downwards, frustrating investors who cite strong deliveries and question the stock's valuation relative to peers. Community members speculate about market manipulation and potential short squeezes while bracing for upcoming earnings. Despite the negative price action, some investors remain optimistic, viewing the current dip as a buying opportunity based on the company's long-term potential.

Walmart, Inc. engages in the retail and wholesale business. The company offers an assortment of merchandise and services at everyday low prices. It operates through the following business segments: Walmart U.S., Walmart International, and Sam's Club. The Walmart U.S. segment operates as a mass merchandiser of consumer products, operating under the Walmart and Walmart Neighborhood Market brands, including walmart.com. The Walmart International segment includes operations of wholly-owned subsidiaries in Canada, Chile, China, and Africa, and majority-owned subsidiaries in India, as well as Mexico and Central America. The Sam's Club segment manages membership-only warehouse clubs and operates samsclub.com. The company was founded by Samuel Moore Walton and James Lawrence Walton on July 2, 1962 and is headquartered in Bentonville, AR.

Walmart Inc

Walmart is trending due to strong Q3 earnings and raised FY26 guidance, sparking bullish sentiment among investors; discussions include the impact of e-commerce growth and a planned move to the Nasdaq. Community members are debating whether Walmart's performance signals broader economic strength or if it's a safe haven during market uncertainty, while also pondering its valuation relative to tech companies.

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is experiencing volatility, sparking debates about a potential market bottom and the influence of large institutional players. Community discussions revolve around whether this dip presents a buying opportunity or signals a deeper correction, with some pointing to macro factors and potential liquidations as drivers. Sentiment is mixed, with bullish and bearish arguments clashing amidst the price swings.

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Vienna, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

Strategy is trending as the price of Bitcoin fluctuates, impacting MicroStrategy's value as a major BTC holder; the community is closely watching key support levels. Discussions revolve around analyst Tom Lee's commentary and potential short squeezes, with some expressing concerns about solvency and potential liquidation. Recent whale activity and overall market sentiment add to the volatility.

Warner Bros. Discovery, Inc. is a premier global media and entertainment company, which engages in the provision of a differentiated portfolio of content, brands, and franchises across television, film, streaming, and gaming. It operates through the following segments: Studios, Networks, Direct-to-Consumer (DTC), and Corporate. The Studios segment includes producing and releasing feature films for initial exhibition in theaters, producing and initial licensing television programs to networks services as well as third parties, distributing films and television programs to various third party, internal television, and streaming services, distribution through the home entertainment market related consumer products, and themed experience licensing and interactive gaming. The Networks segment focuses on domestic and international television networks. The DTC segment is involved in premium pay-television and streaming services. The company was founded on June 17, 1985 and is headquartered in New York, NY.

Warner Bros. Discovery Inc - Ordinary Shares - Class A

Warner Bros Discovery Inc

WBD is trending amid speculation around potential acquisition bids, particularly with a deadline approaching, fueling community discussion about possible outcomes and deal prices. Massive blocks of purchases are being noted, with chatter focusing on potential market manipulation and the involvement of key players like Comcast and Paramount Skydance.  News of HBO renewing a Game of Thrones series has also sparked some positive sentiment.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron is trending as the community debates whether its recent surge is overextended, despite a UBS price target boost. The stock's movements are tied to the broader AI narrative, particularly rising memory prices and potential supply constraints driven by demand for AI data centers. Traders are closely watching for management comments at an upcoming conference and Nvidia's earnings report for further catalysts.

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is trending amid significant price volatility, with community chatter focused on identifying the bottom and anticipating the next launch catalyst. Concerns around potential delays and market manipulation are contrasted by bullish arguments highlighting institutional ownership and long-term potential in the space-based mobile network sector. Investors are closely watching for company announcements and launch dates to drive future price movement.

ProShares Trust - ProShares UltraPro QQQ 3x Shares

ProShares UltraPro QQQ

TQQQ is trending due to market volatility following mixed earnings reports from major tech companies and uncertainty surrounding interest rates and trade relations. Traders are actively discussing potential support and resistance levels, as well as strategies for navigating the current market swings. The overall sentiment appears cautiously optimistic, with many anticipating a potential rebound.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Sarepta Therapeutics (NASDAQ:SRPT) Stock Price Down 5.3% - What's Next?

Sarepta Therapeutics (NASDAQ:SRPT) Shares Down 5.3% - Time to Sell...

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of...

Raiffeisen Bank International AG Has $723,000 Stock Position in Sarepta Therapeutics, Inc. $SRPT

Raiffeisen Bank International AG boosted its stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 137.4% in the second quarter, according to the company in its most recent disclosure...

Bank of New York Mellon Corp Sells 641,805 Shares of Sarepta Therapeutics, Inc. $SRPT

Bank of New York Mellon Corp decreased its stake in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 49.7% during the second quarter, according to its most recent filing with the...

FDA Restricts Use of Sarepta's Gene Therapy, Adds Safety Warnings

SRPT's Elevidys gets a sharply narrowed FDA label with new liver safety warnings that reshape how the gene therapy can be used.

<ul class="summary-bullets"><li>FDA added a boxed warning to Elevidys after two pediatric deaths and imposed stricter monitoring rules.</li><li>Use of gene therapy is now limited to walking DMD patients aged four and older.</li><li>The update deepens a tough stretch for Sarepta following a failed trial and declining Elevidys revenue.</li></ul>Sarepta Therapeutics shares fell over 1% in premarket trading on Monday after the U.S. Food and Drug Administration approved new labeling for the company’s gene therapy Elevidys, adding its most serious safety warning and sharply narrowing the group of Duchenne muscular dystrophy (DMD) patients eligible to receive the drug.<h2 class="st-heading-2">FDA Tightens Restrictions Following Two Deaths</h2>The agency added a boxed warning to Elevidys after two non-ambulatory pediatric patients died from acute liver failure following treatment. The revised label removes authorization for all non-ambulatory patients, limiting use to walking patients aged four and older.In July, Sarepta had voluntarily paused distribution of the $3.2 million therapy for non-ambulatory patients after regulators issued a safety alert. The new labeling now formalizes that restriction and further shrinks the potential market for the treatment.Parent Project Muscular Dystrophy, a major advocacy group, said the update “serves as a reminder that while gene therapy breakthroughs bring promise and hope, serious questions remain about the safety and long-term outcomes of these therapies,” adding that the changes give families “a clearer understanding of who is eligible … and what monitoring is required,” according to a Reuters&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-adds-strongest-warning-sarepta-gene-therapy-after-fatal-liver-injuries-2025-11-14/">report</a>.&nbsp;<h2 class="st-heading-2">Expanded Monitoring And New Post-Market Study Required</h2>Under the revised label, patients must undergo weekly liver function tests for at least three months, and remain close to an appropriate medical facility for two months after treatment.The FDA is also requiring Sarepta to run an observational study involving about 200 DMD patients, tracking liver function and safety outcomes for at least 12 months after receiving Elevidys.<h2 class="st-heading-2">Setback Caps A Difficult Year For Sarepta</h2>The label revision follows a string of setbacks for the company. Earlier this month, Sarepta said its Phase 3 ESSENCE trial for two other DMD drugs, Amondys 45 and Vyondys 53,&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/sarepta-therapeutics-stock-crashes-after-hours-on-dmd-trial-failure-q3-print/cL2FDdvR3Ce">failed to meet its main goal</a>, showing no statistically significant benefit on stair-climb speed after 96 weeks.The company attributed part of the disappointing outcome to trial disruptions during the pandemic, stating that results looked more favorable when data affected by the pandemic was excluded.Financial pressures have also intensified. In the third quarter, revenue declined to $399.4 million from $467.2 million a year earlier, in part due to reduced Elevidys sales following June’s suspension for non-ambulatory patients. Sarepta posted a $179.9 million net loss, reversing last year’s profit, while cash reserves dropped to $865 million from $1.5 billion.<h2 class="st-heading-2">Stocktwits Bulls See Room For A Run</h2>On Stocktwits, retail sentiment for Sarepta was ‘neutral’ amid ‘low’ message volume.<figure class="image"><img style="aspect-ratio:962/140;" src="https://news.stocktwits-cdn.com/srpt_ss_jpg_9a8ec81686.webp" alt="srpt ss.jpg" width="962" height="140"><figcaption>SRPT sentiment and message volume as of November 17 | Source: Stocktwits</figcaption></figure>One user said, “$25 is a reasonable target for this week. Next week we can start talking 30+.”<stembedurl>https://stocktwits.com/Roaring_Capybara/message/636403055</stembedurl>Another user said, “lets have a great week! Hopefully the biotech sector will continue to enjoy a good influx of money, acquisitions continue, and more good news for SRPT!“<stembedurl>https://stocktwits.com/Plowmaster/message/636395126</stembedurl><a href="https://stocktwits.com/symbol/SRPT">Sarepta’s stock</a> has declined 85% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Sarepta Therapeutics logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Sarepta Stock Slides Premarket After New FDA Warning Shrinks Market For Its $3.2M DMD Gene Therapy

FDA added a boxed warning to Elevidys after two pediatric deaths and imposed stricter monitoring rules.

Equity

Sarepta Therapeutics (NASDAQ:SRPT) Stock Price Up 8% - Time to Buy?

Sarepta Therapeutics (NASDAQ:SRPT) Shares Up 8% - Here's Why...

2 Beaten-Down Stocks to Avoid Right Now

Key PointsIntellia Therapeutics and Sarepta Therapeutics have hit serious setbacks potentially linked to their treatments...

Sarepta Shares Jump After FDA Approves Updated Elevidys Label

Sarepta Therapeutics shares jumped after the FDA issued a new boxed warning for Elevidys.read more...

Sarepta Announces FDAs Approval of Updated ELEVIDYS Prescribing Information

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced an update to the prescribing information for ELEVIDYS (delandistrogene...

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Current Price	$16.56
Prev Close	$16.39
Open	$16.58
Dividend Yield	0.00%
50-Day Moving Average	$20.23
Beta	1.05
Avg. Volume	5.2M
PE Ratio	-5.67

52-Week High	$138.81
52-Week Low	$10.42
Market Capitalization	$1.72B
EPS (Annual)	$2.34
Price to Book	1.30
Revenue Per Employee	$1.39M
Enterprise Value/EBITDA	N/A

SRPT
Sarepta Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest SRPT News

SRPTSarepta Therapeutics Inc